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ABSTRACT: Intentional or accidental release (direct disposal)
of high loads of unused pharmaceuticals into wastewater can go
unnoticed. Here, direct disposal of a pharmaceutical drug via the
sewer network was identified for the first time using wastewater
analysis. An irregularly high load of the antidepressant fluoxetine
in raw wastewater (10.5 ± 2.4 g d−1) was up to 11 times greater
than any other day. National prescription data revealed a
predicted daily fluoxetine load for the studied treatment works to
be 0.4−1.6 g d−1. Enantio-selective analysis showed the high load
of fluoxetine was present as a racemic mixture, which is typical
for fluoxetine in dispensed formulations. As fluoxetine undergoes
stereoselective metabolism within the body, a racemic mixture in
wastewater suggests a nonconsumed drug was the major
contributor of the high load. This was confirmed by its major
metabolite norfluoxetine whose load did not increase on this day. Considering the most commonly prescribed formulation of
fluoxetine, this increased load accounts for the disposal of ∼915 capsules. Furthermore, as fluoxetine is prescribed as one capsule
per day, disposal is unlikely to be at the patient level. It is postulated that direct disposal was from a facility which handles larger
quantities of the drug (e.g., a pharmacy).
1. INTRODUCTION
In 2001, wastewater analysis has been first proposed for
community wide estimation of drug use.1 This approach has
been applied in numerous studies to date, mainly for illicit drug
use estimates throughout Europe.2,3 The same approach has
been applied to pharmaceuticals.4,5 However, notable discrep-
ancies between consumption estimates from wastewater
analysis and prescription information have been observed for
some compounds.4,5 For example, the study of 12 prescription
drugs at a wastewater treatment works (WwTW) in the UK
found consumption estimates from wastewater analysis can
range from 12 to 514% of what is expected from prescription
data.4 Possible reasons for inaccurate pharmaceutical drug
consumption estimates from wastewater analysis includes the
abuse of counterfeit drugs,6 the unavailability of information on
drugs dispensed in hospitals, spatial differences in prescription/
use (where national prescription information is used), prescribed
drugs going unused, or drugs being directly disposed into the
wastewater system.7
Several studies have found direct disposal of unused phar-
maceutical drugs to the sewer system as a viable route into
wastewater at both the patient8,9 and pharmacy level.10 These
studies rely on patients and pharmacies completing question-
naires on their disposal practices. However, to date there has
been very little/no evidence of direct disposal of pharmaceutical
drugs identified through wastewater analysis. This is because
observing directly disposed drugs at the patient level is unlikely
to provide a significant change to the composition of the
wastewater itself. Observing direct disposal will be strongly
dependent on the pharmacokinetics of the pharmaceutical in
question, the extent of its usage within the population and the
size of the receiving WwTW. On the other hand, direct disposal
by a pharmacy will only be observed fortuitously as it is likely
to occur infrequently. Furthermore, if observed by wastewater
analysis, other than a high compound load there may not be
further supporting evidence to adequately diagnose direct
disposal. If the pharmaceutical is only available via prescription,
national prescription information can be used to estimate the
load of that drug in wastewater.
Enantio-selective analysis is an indispensable tool for resolving
certain environmental problems. It can be used to identify the
source of chiral drug loads found in wastewater. Directly dis-
posed drug loads can be distinguished from consumed drug
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loads by determining the enantiomeric distribution of the chiral
drug in question.7 This relies on the pharmaceutical drug in
question being dispensed in a known enantiomeric form and it
undergoing stereoselective changes within the body during
metabolism. Vazquez-Roig et al.11 used enantioselective analysis
to tentatively propose direct disposal of atenolol where a
moderately higher average daily load was observed. Monitoring
human metabolites of the compound in question can also be
used to help distinguish between directly disposed and con-
sumed drugs.12 The clearest case of direct disposal identified
through wastewater analysis was by Emke et al.7 Here, high
daily loads of the illicit stimulant 3,4-methylenedioxy-
methamphetamine (MDMA) or ecstasy were found to be
present in wastewater as a racemic mixture. This was observed
following a police raid of an illegal production facility within the
catchment.7 Nevertheless, to date there have been no cases with
strong supportive evidence of the direct disposal of a
pharmaceutical drug using wastewater analysis.
Directly disposed drugs can also have a significant impact
upon the receiving environment if they are not sufficiently
removed during wastewater treatment. The antidepressant
fluoxetine has been identified as a compound of risk for the
aquatic compartment in some studies.13,14 This is due to it
being detected in river waters or predicted to be present in river
waters at concentrations above predetermined predicted-no-
effect-concentrations (PNECs). Oakes et al.13 proposed a
fluoxetine PNEC of 0.012 μg L−1. This was derived using a
lowest observed effect concentration (LOEC) of ≤0.6 μg L−1
for the chlorophyte Desmodesmus subspicatus and an assessment
factor of 50.13 In freshwater ecosystems globally, fluoxetine has
been reported at median concentrations of 0.020 μg L−1.15
Considering the small differences between the proposed PNEC
and concentrations observed in the environment, direct
disposal of the drug can influence whether or not the PNEC
of fluoxetine is exceeded.
In our study, during an eight day sampling period of raw
wastewater at a municipal WwTW in South-West England, a
high load of the antidepressant fluoxetine was observed. It was
postulated that this was the result of direct disposal of the drug
rather than increased consumption. Therefore, the aim of this
study was to diagnose this high load of fluoxetine as direct
disposal. This was assessed by investigating the following:
i) UK prescription information for fluoxetine
ii) The enantiomeric distribution of fluoxetine in raw
wastewater
iii) The relationship between fluoxetine and its major
metabolite norfluoxetine
These findings were compared to a seven day sampling
period at the same WwTW where no direct disposal was
suspected. This study is the first to demonstrate with sufficient
supporting evidence the direct disposal of a prescribed
pharmaceutical drug using wastewater analysis. Using this
information, we propose a new framework to distinguish
between consumed and nonconsumed (directly disposed) drug
loads in wastewater. Finally, the risk posed by direct disposal in
the environment was evaluated by applying established
environmental risk assessment calculations.
2. MATERIAL AND METHODS
2.1. Materials. R/S-(±)-Fluoxetine and norfluoxetine
(Table S1) were purchased from Sigma-Aldrich (Gillingham,
UK) and the internal standard R/S-(±)-fluoxetine-D5 from
TRC (Toronto, Canada). Methanol (MeOH) was HPLC grade
and purchased from Sigma-Aldrich (Gillingham, UK). Water
(H2O) was of 18.2 MΩ quality (Elga, Marlow, UK). All
glassware was deactivated using 5% dimethylchlorosilane in
toluene (Sigma-Aldrich, Gillingham, UK). Ammonium acetate
(NH4OAc), formic acid (HCOOH), and acetic acid (1.0 M)
used in the preparation of mobile phases were also purchased
from Sigma-Aldrich. Oasis HLB (60 mg, 3 mL) solid phase
extraction (SPE) cartridges were purchased from Waters
(Manchester, UK).
2.2. Analytical Methodologies. Briefly, samples for SPE
were brought to room temperature and filtered (0.7 μm), and
50 mL aliquots were spiked with 50 ng of fluoxetine-D5. These
were loaded onto preconditioned Oasis HLB cartridges, dried,
and eluted using 4 mL of MeOH. Extracts were then dried
under nitrogen and reconstituted in 500 μL of 80:20
H2O:MeOH for the determination of whole drug concen-
trations. A fully validated method utilizing ultraperformance
liquid chromatography tandem mass spectrometry using a
Waters Acquity UPLC system (Manchester, UK) coupled
to a Xevo TQD Triple Quadrupole Mass Spectrometer
(Waters, Manchester, UK) was applied. A full description of
the method is available in Petrie et al.16 Recoveries of fluoxetine
and norfluoxetine ranged from 95 to 111%, with method
quantitation limits of 2.1 to 2.5 ng L−1 (Tables S2 and S3).
To investigate the enantiomeric fraction (EF) of fluoxetine,
SPE cartridges were prepared in the same way. However,
following elution and drying of MeOH extracts, reconstitution
was in 500 μL of the appropriate mobile phase used for
enantioselective separation (4 mM NH4OAc in MeOH
containing 0.005% HCOOH). For separation, a Chirobiotic
V column (100 × 2 mm; 5 μm internal diameter) was used, as
described in Evans et al.17 The EF of fluoxetine was calculated
according to eq 1
= +
+ + −
S
S R
EF
( )
[ ( ) ( )] (1)
where EF is the enantiomeric fraction, S(+) is the peak area of
S-(+)-fluoxetine accounting for the response of S-(+)-fluox-
etine-D5, and R(−) is the peak area of R-(−)-fluoxetine
accounting for R-(−)-fluoxetine-D5. The uncertainty of EF
measurement for fluoxetine in raw wastewater was <0.05.17
2.3. Wastewater Treatment Works. A trickling filter
WwTW in South-West England was studied. This receives
mainly municipal wastewater with a population equivalent (PE)
of 105,847. Raw wastewater was collected during an eight day
monitoring campaign in December 2014 (08/12/14 to
15/12/14) and a seven day monitoring campaign in June
2015 (03/06/15 to 09/06/15). Samples were collected post
primary screens but before primary sedimentation tanks.
Volume paced composites were operated with a mean sampling
frequency of 15 min (i.e., 96 subsamples throughout 24 h).
This conservative sampling frequency was selected to ensure
sampling error distributions were unbiased and <20%.18 The
number of toilet flushes or “pulses” (p) per day estimated for
fluoxetine in this WwTW was ∼6600 (>100 p d−1 is required
for representative information using volume-paced composites
with a 15 min collection frequency).18 Subsamples were cooled
on collection to <4 °C to limit biological activity. On the first
Monday of the December sampling campaign (08/12/14),
hourly grab samples were also collected between 8:00 and 0:00
(n = 17). Upon collection, all samples were filtered and subject
to SPE immediately.
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2.4. Environmental Risk Assessment. Environmental risk
assessment of fluoxetine in receiving river water was undertaken
with reference to the Guideline on the Environmental Risk
Assessment of Medicinal Products for Human Use.19 The ratio
between the predicted environmental concentration (PEC) and
PNEC was calculated as means of quantifying the risk posed.
Ratios >1 require further evaluation of the fate of the drug
and/or its metabolites in the aquatic environment. The PEC
(μg L−1) was calculated using the following equations with
prescription information (2) and wastewater analysis (3),
respectively
= × ×
× ×
S R
Q
PEC
Load
PE DFPrescription
PRES
(2)
= ×
× ×
R
Q
PEC
Load
PE DFWaste water analysis
INF
(3)
Here LoadPRES is the maximum predicted load based on
prescription information (accounting for the % dose excreted
unchanged) (μg d−1), LoadINF is the daily load of fluoxetine in
the aqueous phase of influent wastewater (μg d−1), S is the
correction factor to account for the fraction of fluoxetine bound
to suspended particulate matter (0.49),4 R is the correction
factor to account for the known removal of fluoxetine during
wastewater treatment at the site in question (0.673), Q is the
total quantity of wastewater per inhabitant (L inh−1 d−1), PE is
the population size contributing to the wastewater, and DF is
the dilution factor of effluent into the river. The PNEC of
fluoxetine was determined according to
=PNEC Tox.
AF (4)
Here Tox. is the lowest available toxicity data (effect
concentration (EC50), lethal concentration (LC50), LOEC, no
observed effect concentration (NOEC)) considering at least
three species type, and AF is the assessment factor (1000 for
EC50 and LC50 and 10 for LOEC and NOEC).
3. RESULTS AND DISCUSSION
3.1. Daily Profile of Fluoxetine and Norfluoxetine in
Raw Wastewater. 3.1.1. Predicted and Measured Daily
Loads of Fluoxetine. On Wednesday of the December
sampling campaign, a fluoxetine load of 10.5 ± 2.4 g d−1 was
observed (Figure 1). This was considerably greater than any
other day (up to 11 times). The consumption of fluoxetine is
not expected to vary greatly throughout the week as it is
unlikely to be used as a drug of abuse which may result in
recreational usage. Furthermore, no significant rainfall or
increased wastewater flows were recorded on this day which
could have resulted in an increased load of fluoxetine flushed
from the sewer network (Table S4). Therefore, it was
postulated that the high load of fluoxetine on Wednesday was
a result of direct disposal. Using UK prescription information,
the daily load of fluoxetine predicted to be observed at a
105,847 PE WwTW in England during December 2014 was
0.4−1.6 g d−1 (Table 1). This was calculated according to eq 5
=
× × ×− ( )( )( )
d
Load
PRES.
PREDICTED
Excretion
100
(100 part .)
100
WwTW PE
Pop .
(5)
Here PRES. is the quantity of drug prescribed nationally
during a calendar month as the free base (g) (Table 1),
Excretion is the quantity of drug excreted unchanged following
consumption (%) (Table 1), part. is the sorption of drug to
suspended particulate matter (%) (Table 1), WwTW PE is the
population equivalent of the wastewater treatment works, Pop.
is the population size to which the prescription information
relates (57,000,000), and d is the number of days in the month
studied. It should be noted that comparison of prescription
information with measured drug loads in raw wastewater can
have discrepancies. For example, a detailed study by Baker et
al.4 at a 3,400,000 PE WwTW in England showed the difference
between calculated fluoxetine loads and estimated loads from
prescription data to be 57%. Furthermore, prescription data
used in our study is at a national scale, and the WwTW studied
here (105,847) represents <2% of the population. Therefore,
there are uncertainties associated when comparing prescription
data with wastewater analysis (e.g., possible spatial trends in
prescription behavior). Nevertheless, a 10.5 g d−1 observed on
Wednesday of the December sampling campaign was +650% of
the maximum predicted load (Figure 1, Table 1). On all other
days, calculated loads ranged from 70 to 180% of the maximum
predicted load.
During a seven day sampling period in June 2015 at the same
WwTW where no significant contributions from direct disposal
were suspected, daily loads ranged from 0.6 to 0.9 g d−1
(LoadPREDICTED = 0.3−1.4 g d−1) (Figure 1, Table 1). Here no
significant contribution of the fluoxetine load is suspected from
direct disposal as the predicted load was not exceeded. This
uniformity of daily fluoxetine load is in good agreement
with previous observations for prescription drugs,4,25,26
including fluoxetine.4 This supports the hypothesis that the
irregularly high load of fluoxetine on Wednesday of the
December sampling campaign was caused by direct disposal
of a large quantity of the drug. To investigate this further,
enantioselective analysis was undertaken to measure the
enantiomeric distribution of fluoxetine in raw wastewater.
3.1.2. Enantio-Selective Analysis as a Tool To Distinguish
between Consumed and Directly Disposed Unused Drugs.
Enantio-selective analysis can be used to help distinguish
between consumed drugs and those directly disposed.7 This is
reliant on the drugs in question being chiral, dispensed in a
known enantiomeric form, and subject to stereoselective
changes to their composition during human metabolism.
Fluoxetine satisfies these criteria as it is dispensed as a racemic
mixture, and human metabolism results in the enrichment of
S-(+)-fluoxetine. This is due to R-(−)-fluoxetine undergoing
faster metabolism in the body than S-(+)-fluoxetine.22 Con-
sequently, an EF of >0.5 would be expected in raw wastewater
containing the consumed drug. Between Thursday and Monday
of the December sampling campaign (11/12/14 to 15/12/14),
EFs ranged from 0.56 to 0.68 (Figure 1). Here fluoxetine
loads were <1.8 g d−1 (estimated load from prescription data =
0.4−1.6 g d−1) demonstrating fluoxetine was consumed, and no
notable direct disposal is suggested. This is in good agreement
with data obtained in June where loads were ≤0.9 g d−1
(LoadPREDICTED = 0.3−1.4 g d−1) and EFs ranged from 0.66 to
0.70 (Figure 1).
On Monday (08/12/14), Tuesday, and Wednesday of the
December sampling campaign where loads were >1.8 g d−1, EFs
were in the range 0.48 to 0.51 (Figure 1). Enantiomeric fractions
close to racemic (0.50) here suggest a large contribution of the
fluoxetine load observed in raw wastewater on these days is
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nonconsumed drugs. This provides further support that the high
load of fluoxetine on Wednesday was caused by direct disposal.
Furthermore, EFs close to 0.50 on Monday and Tuesday suggest
that direct disposal also occurred on these days. Interestingly,
due to inherent discrepancies in comparing prescription data
with measured drug loads,4,5 direct disposal would not have been
suspected on either Monday (8/12/14) or Tuesday of the
December sampling campaign without enantioselective analysis.
3.1.3. Distinguishing between Consumed and Non-
consumed Drugs by Metabolite Profiling. A further piece of
Table 1. Prescription, Metabolism, and Predicted Daily Loads of Fluoxetine and Norfluoxetine at a 105,847 Population
Equivalent WwTW in the UK during December 2014 and June 2015
fluoxetine
prescribed as
free base (kg) LoadPREDICTED
g (g d‑1)
compound
Dec
2014
June
2015
excretion of
fluoxetine
dose (%)
known
metabolites
enantiomeric
distribution in urine
(human)
partitioning
to influent
solids (%) Dec 2014 June 2015
predicted
fluoxetine:norfluoxetine
ratio
fluoxetine 488a 430b 2.5−11c,d norfluoxetinee enriched with S-(+)
enantiomer,
EF > 0.5e
51f 0.4−1.6 0.3−1.4
norfluoxetine 7−10c,d 62f 0.8−1.2h 0.7−1.1h 0.3−1.9
aNational Health Service.20 bNational Health Service.21 cCaccia t al.22 dTaylor et al.23 eBergstrom et al.24 fBaker et al.4 gAqueous phase only, see eq 5
for calculation. hTo calculate the predicted load of norfluoxetine, the difference in molecular weight between norfluoxetine and fluoxetine is
considered as % excretion considers number of moles over mass.
Figure 1. Daily fluoxetine load and EF (A) and norfluoxetine load and the fluoxetine:norfluoxetine ratio (B) during week long sampling campaigns
in December 2014 and June 2015, respectively. The solid red line outlines a racemic EF (i.e., 0.5), and the broken red line shows the predicted
fluoxetine:norfluoxetine ratio range for consumed fluoxetine (see Table 1). Days where direct disposal has been identified are highlighted with a blue
background.
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evidence which can help distinguish between consumed and
nonconsumed drugs in raw wastewater are their metabolites.
Metabolites are excreted together with the parent drug in
known quantities relative to one other following consumption.
The main metabolite of fluoxetine is norfluoxetine.22 The
relationship between fluoxetine and norfluoxetine in raw
wastewater can therefore be used to help distinguish between
consumed and nonconsumed fluoxetine drug loads. Daily loads
of norfluoxetine ranged from 1.1 ± 0.1 to 1.4 ± 0.1 g d−1 during
the eight day sampling period in December (LoadPREDICTED =
0.8−1.2 g d−1) (Figure 1). No relationship was observed
between fluoxetine and norfluoxetine loads which could have
suggested increased consumption resulted in the high loads of
fluoxetine observed. The predicted ratio of fluoxetine to
norfluoxetine expected in the aqueous phase of raw wastewater
following consumption is 0.3−1.9 (Table 1). On days where no
significant direct disposal was proposed, the fluoxetine:nor-
fluoxetine ratios ranged from 0.8 to 1.3. This is in agreement
with the June sampling period where fluoxetine:norfluoxetine
ratios were between 1.0 and 1.4. However, on both Monday
(08/12/14) and Wednesday of the December sampling
campaign the fluoxetine:norfluoxetine ratio was ≥2.6 providing
further support that fluoxetine was directly disposed on these
days (Figure 1B). Most notably, the fluoxetine:norfluoxetine
ratio on Wednesday was 8.3.
3.2. Hourly Variations of Fluoxetine and Norfluoxetine
in Raw Wastewater. During the first Monday (08/12/14) of
the December sampling campaign, hourly grab samples were
collected between 8:00 and 0:00 h (n = 17). This provided
the opportunity to investigate the hourly variability in fluoxetine
and norfluoxetine load during a day where direct disposal of the
parent drug was suspected. Here the measured load was greater
than the predicted daily load (2.9 g d−1 versus 0.4−1.6 g d−1);
an EF close to 0.50 and a fluoxetine:norfluoxetine ratio of
2.6 all indicated direct disposal had occurred within the
catchment on this day (Figure 1). Grab sampling revealed that
the hourly load of fluoxetine varied from 0.06 to 0.64 g h−1,
with highest loads generally observed between 08:00 and
15:00 h (Figure 2A). During these times, an enrichment of
S-(+)-fluoxetine was not observed, and the EF of fluoxetine was
∼0.50 ± 0.02 (Figure 2A). This suggests a large contribution of
the fluoxetine load at these times was nonconsumed drugs.
This was supported by the behavior of norfluoxetine which did
not show such high variability in load indicating a constant (or
unchanged) level of fluoxetine consumption in the studied
population. Norfluoxetine loads varied from 0.04 to 0.07 g h−1
throughout the day (Figure 2B). Considering fluoxetine
typically has a single daily dose and a half-life of between 2
and 3 days,27 this low variability in metabolite load is not
surprising. Between 08:00 and 15:00 h the fluoxetine:nor-
fluoxetine ratio was >1.9 supporting the proposal that
fluoxetine loads observed at these times were mainly present
as nonconsumed drugs. From 16:00 h onward, fluoxetine and
norfluoxetine loads as well as EFs were indicative of
consumption only (Figure 2). The length of time wastewater
takes to travel from the point of entry into the sewer network
(i.e., a household) within the catchment to the WwTW can
vary from <30 min to ∼6 h. Consequently, it is difficult to
predict exactly when direct disposal took place on this day
other than it being prior to 08:00 h.
3.3. A New Framework To Distinguish between
Consumed and Nonconsumed (Directly Disposed)
Drugs in Wastewater. Only a few studies reported in the
literature have proposed evidence for the direct disposal of
drugs (Table 2).7,11,12 There are a number of reasons for this:
(i) direct disposal at the patient level (e.g., of a daily dose) is
unlikely to have sufficient impact upon a 24 h composite
sample collected from a medium to large sized WwTW,
particularly if the drug in question is a high usage compound
(and has a high excretion rate as the unchanged drug following
consumption), (ii) the infrequent disposal of larger quantities
of drugs by a patient (weekly or monthly dose), hospital, or
pharmacy cannot be predicted and will only be observed
fortuitously, and (iii) due to analytical or other limitations, the
disposed drug may itself not be studied or (iv) further supporting
evidence of direct disposal (e.g., enantiomeric distribution and
determination of metabolites) may not be attainable.
Andreś-Costa et al.12 observed high loads of the illicit
stimulant cocaine during a week-long sampling event at a
WwTW in Spain. This corresponded with a higher than
anticipated parent drug:metabolite ratio. Cocaine:benzoylecgo-
nine ratios ranged from 1.6 to 2.0 and are considerably greater
than the expected ratio of 0.2−0.5 (Table 2).12 This was
supported by newspaper reports of police raiding an illegal
production facility within the catchment. Similarly, higher than
Figure 2. Hourly variability of fluoxetine load and EF (A) and
norfluoxetine load and the fluoxetine:norfluoxetine ratio (B) during
the first Monday (08/12/14) of the December 2014 sampling
campaign from Figure 1. The solid red line outlines a racemic EF (i.e.,
0.5), and the broken red line shows the predicted fluoxetine:
norfluoxetine ratio range for consumed fluoxetine (see Table 1).
Times where direct disposal has been identified are highlighted with a
blue background.
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typical MDMA loads (∼20 times) at a WwTW in The
Netherlands coincided with a police raid of an illegal
production facility (Table 2).7 In this case, enantioselective
analysis was used to help diagnose the direct disposal of
MDMA. EFs of MDMA was ∼0.50 (racemic mixture) when
high loads were observed. Where consumption is assumed
during a baseline week for comparison purposes EFs were
>0.57.7 In the literature, only one study provides some evidence
for direct disposal of a pharmaceutical drug. Vazquez-Roig
et al.11 reported average daily loads for the beta-blocker atenolol
of 1.3 g d−1 1000−1 inhabitants. This was higher than other
WwTWs studied in the area which received loads of 1.0 g d−1
1000−1 inhabitants. Higher loads were again supported with
racemic EFs (Table 2). However, no previous study which has
postulated direct disposal from wastewater analysis has been
able to provide strong supportive evidence of drug use
information (e.g., prescription data), parent drug/metabolite
relationships, and enantiomeric determinations. These param-
eters were used to establish a framework for distinguishing
between consumed and nonconsumed (directly disposed)
prescription drugs using wastewater analysis (Figure 3). This
framework can be applied to findings from routine 24 h
composite sampling to help identify directly disposed drug
loads. Applying this framework in our study, direct disposal was
confirmed on Monday (08/12/14) and Wednesday of the
December sampling period. Direct disposal could not be
confirmed on Tuesday as the fluoxetine:norfluoxetine ratio did
not exceed the predicted ratio of 0.3−1.9 based on
consumption (Table 1). Application of this framework requires
care as it will not be directly applicable to all chiral drugs. For
example, ibuprofen can be dispensed in more than one enantio-
meric form - as a racemic mixture or in the enantiomerically
pure form. This makes it difficult to predict the enantiomeric
form expected in wastewater. On the other hand, the
metabolite of a parent drug can also be dispensed as a separate
pharmaceutical (e.g., desvenlafaxine). Therefore, the framework
should act as a starting point for investigating the disposal of
pharmaceutical drugs and adapted for the specific drug under
investigation.
Using the data obtained on Wednesday, the quantity of drug
formulations estimated to be directly disposed was calculated
using eq 6
=
− × −( )
No. of formulations
(Load Load )
Dose
PREDICTED
100
(100 part .)
(6)
Here Load is the calculated daily load at the WwTW (g),
LoadPREDICTED is the highest predicted daily load based on eq 5
(g), part. is the sorption of drug to suspended particulate
matter (%, note that partitioning to suspended particulate
matter could be concentration dependent), and Dose is the
dose of drug per formulation (g). The most widely dispensed
formulation of fluoxetine in the UK is capsules containing
20 mg of active ingredient.20 This formulation accounted for
96% of all fluoxetine items prescribed during December 2014.
Using this information, the number of capsules estimated to be
directly disposed of on Wednesday is ∼915 capsules. Further-
more, as the prescribed dose is one capsule per day, this
number of capsules accounts for an individual’s prescription of
>2.5 years. This suggests direct disposal is unlikely to be at
the patient level. Disposal of such a large number of capsulesT
ab
le
2.
Su
sp
ec
te
d
D
ir
ec
t
D
is
po
sa
l
of
D
ru
gs
R
ep
or
te
d
in
th
e
Li
te
ra
tu
re
a
di
re
ct
di
sp
os
al
pr
op
os
ed
ba
se
lin
e
in
fo
rm
at
io
n
us
ed
fo
r
co
m
pa
ris
on
(n
o
di
re
ct
di
sp
os
al
su
sp
ec
te
d)
dr
ug
cl
as
s
of
dr
ug
du
ra
tio
n
Lo
ad
(g
d‑
1 )
EF
pa
re
nt
dr
ug
:
m
et
ab
ol
ite
du
ra
tio
n
Lo
ad
(g
d‑
1 )
EF
pa
re
nt
dr
ug
:
m
et
ab
ol
ite
fu
rt
he
r
in
fo
rm
at
io
n
re
f
flu
ox
et
in
e
an
tid
ep
re
ss
an
t
M
on
-M
on
(D
ec
20
14
)
0.
95
−
10
.5
4
0.
48
−
0.
68
0.
8−
8.
3
W
ed
-T
ue
s
(J
un
e
20
15
)
0.
58
−
0.
91
0.
67
−
0.
70
1.
0−
1.
4
pr
ed
ic
te
d
da
ily
lo
ad
us
in
g
D
ec
20
14
pr
es
cr
ip
tio
n
da
ta
=
0.
4−
1.
6
g
d−
1
th
is
st
ud
y
at
en
ol
ol
be
ta
-b
lo
ck
er
on
e
w
ee
k
(2
01
2)
1.
3b
0.
50
on
e
w
ee
k
(2
01
2,
di
ffe
re
nt
W
w
T
W
)
1.
0b
>0
.5
0
V
az
qu
ez
-R
oi
g
et
al
.11
M
D
M
A
ill
ic
it
st
im
ul
an
t
on
e
w
ee
k
(2
01
1)
18
4
0.
50
on
e
w
ee
k
(2
01
0)
9.
3
>0
.5
7
po
lic
e
ra
id
ill
eg
al
pr
od
uc
-
tio
n
fa
ci
lit
y
w
ith
in
ca
tc
hm
en
t
Em
ke
et
al
.7
am
ph
et
am
in
e
ill
ic
it
st
im
ul
an
t
on
e
w
ee
k
(2
01
1)
14
31
0.
52
on
e
w
ee
k
(2
01
0)
99
0.
52
Em
ke
et
al
.7
co
ca
in
e
ill
ic
it
st
im
ul
an
t
Fr
i
an
d
Su
n
at
tw
o
se
pa
ra
te
W
w
T
W
s
(2
01
3)
37
5−
32
92
1.
6−
2.
0
se
ve
ra
l
w
ee
ks
(2
01
1
an
d
20
12
)
11
0−
46
4
0.
2−
0.
5
po
lic
e
sh
ut
do
w
n
ill
eg
al
pr
od
uc
tio
n
fa
ci
lit
y
w
ith
-
in
ca
tc
hm
en
t
A
nd
re
ś-
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on 1 day is more likely to be by a facility which handles and
dispenses a large quantity of pharmaceutical drugs (e.g., a
pharmacy). In this catchment there are no registered phar-
maceutical production companies. A study by Tong et al.10
found that 3.2% of 285 community pharmacies in New Zealand
disposed of unused solid medications via the toilet or sink.
Although this may not be directly comparable to current
disposal practices in the UK, this is a possible route of entry
for the relatively large quantity of unconsumed fluoxetine
observed on Wednesday. Current EU directives only outline
that member states shall ensure that appropriate collection
systems are in place for medicinal products that are unused or
have expired.28
3.4. Environmental Risk Assessment. To assess the
potential impact of fluoxetine in the environment, established
environmental risk assessment protocols were applied.19 It
should be noted that current environmental risk assessment can
be inaccurate as it does not consider the impact of mixtures of a
number of different compounds or the enantio-specific toxicity
of chiral drugs. For example, enantio-specific toxicity has been
observed for fluoxetine toward some aquatic species.29,30
Nevertheless, these established environmental risk assessment
calculations have been applied here to compare the possible
environmental impact of consumed and directly disposed drug
loads. PECs were calculated taking into account site specific
flow data (wastewater and receiving river). This was calculated
using prescription data and wastewater analysis from December
2014 and June 2015. Using available toxicity data in the
literature, the lowest derived PNEC was calculated to be
0.010 μg L−1 (Table S5). This was determined using toxicity
data from studies using racemic fluoxetine. Therefore, there will
be a degree of uncertainty here as directly disposed and con-
sumed fluoxetine will have different enantiomeric distributions
when entering the environment, and, as discussed previously,
enantio-specific toxicity of fluoxetine is known to occur.29,30
The PEC of fluoxetine for the load observed on Wednesday
(December 2014) where direct disposal was identified was
0.0044 μg L−1 (Table 3). This corresponded to a PEC/PNEC
of 0.44, and therefore low risk is assumed despite a high load of
the drug observed. This is attributed to the high dilution in
wastewater (354 L inh−1 d−1) and in the receiving river
(44 times) at this site during winter. No seasonal bias is
expected for the direct disposal of fluoxetine. Therefore, if the
directly disposed load (10.5 g d−1) is applied to June conditions
at the same WwTW (wastewater volume of 235 L inh−1 d−1
and a riverine dilution factor of 18), the PEC/PNEC is 1.59
(Table 3). The action limit of 1 is exceeded, and further
investigation is needed. It should be noted that many WwTWs
have similar or lower wastewater and river dilution ratios than
those reported here. For example, seven of 16 WwTWs
previously studied in the UK had river dilution factors of ≤7,
with two of these sites having dilution factors of one (i.e., no
dilution).31 Therefore, directly disposed drugs are expected to
have an even greater environmental impact here. On the other
hand, the PEC will be lower at sites which employ other
wastewater treatment options (e.g., activated sludge) which are
considered more effective in removing fluoxetine than trickling
filters. However, greater stereoselective changes may be
observed which need to be taken into account.
Finally, if the PEC of fluoxetine is calculated using UK
prescription data and default conditions (wastewater volume of
200 L inh−1 d−1 and a riverine dilution factor of 10)19 as a
means of prioritizing compounds for investigation, a concen-
tration of 0.005 μg L−1 is derived (Table 3). Thus, the PEC/
PNEC of fluoxetine is determined to be 0.50. This is similar to
a study by Oakes et al.13 where a PEC/PNEC ratio of 0.83 was
calculated from prescription data for Sweden. In both cases the
PEC/PNEC action limit of 1 is not exceeded, and this
compound may not be prioritized for further investigation here.
However, if the directly disposed load is applied to default
Figure 3. Proposed framework to distinguish between consumed and directly disposed prescription drugs in wastewater.
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dilution conditions19 (to a 105,847 population equivalent
WwTW), the PEC/PNEC is calculated to be 3.35 (Table 3).
Therefore, the environmental risk posed by pharmaceutical
drugs cannot be fully appreciated by calculating PECs on
prescription data alone (or by applying default dilution ratios).
It is recommended that future environmental risk assessment
must consider the possibility of directly disposed drugs entering
wastewater (and their stereoselective composition), even
though the frequency of these events and their severity in
terms of total drug quantity disposed are difficult to predict.
Consequently, a more integrated approach toward environ-
mental risk assessment may be needed by considering disposal
practices of patients, hospitals, and pharmacies (and their
number/size, etc.) within the catchment area under study.
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Table S1. Physico-chemical properties of fluoxetine and norfluoxetine 
Drug/metabolite Molecular 
weight (g mol-
1) 
Chemical structure Water 
Solubility 
(mg L-1)i 
Log Kowii Log Kociii Log Dowiv Henry's Law 
Constant 
(atm m3mol-
1)v 
Vapour 
Pressure 
(Torr)vi 
pKa 
(Most basic)vii 
Fluoxetine 309.33 
 
60.3 4.65 8.90E-08 1.92 8.90E-08 1.88E-06 10.05±0.10 
Norfluoxetine 295.30 
 
- - - 1.54 - 5.21E-06 9.05±0.13 
iAs calculated by EPI Suite1 at 25°C 
iiAs calculated by EPI Suite1 (KOWWIN v1.68 estimate) 
iiiAs calculated by EPI Suite1 based on Log Kow 
ivAs calculated by Marvin Beans2 at pH 7.5 
vAs calculated by EPI Suite1 based on Bond SAR method 
viAs stated on Scifinder calculated using Advanced Chemistry Development (ACD/Labs) Software v11.02 (©1994-2015 ACD/Labs)3  
viiAs stated on Scifinder calculated using Advanced Chemistry Development (ACD/Labs) Software v11.02 (©1994-2015 ACD/Labs) at 25°C3  
*Denotes chiral centre 
 
 
  
* 
* 
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Table S2. Mass spectrometry information for the determination of fluoxetine and norfluoxetine  
Drug/metabolite 
Molecular 
ion (m/z) 
Daughter 
1 (m/z) 
Cone 
voltage 
(V) 
Collision 
energy 
(eV) 
Daughter 
2 (m/z) 
Cone 
voltage 
(V) 
Collision 
energy 
(eV) 
Ion 
ratio 
Internal 
standard 
Fluoxetine 310.2 44.1 34 10 148.1 34 10 14.9 
Fluoxetine 
D5 
Norfluoxetine 296.1 134.1 18 6 - - - - 
Fluoxetine 
D5 
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Table S3. Method validation parameters for fluoxetine and norfluoxetine in influent wastewater 
Drug/metabolite IDL (ng L-1) IQL (ng L-1) Recovery (%) 
Matrix 
suppression 
(%) 
MDL (ng L-1) MQL (ng L-1) 
Fluoxetine 0.01 0.05 111 54 0.50 2.52 
Norfluoxetine 0.01 0.05 95 55 0.42 2.12 
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Table S4.  Wastewater flow data and rainfall during December 2014 and June 2015 sampling campaigns 
Measured variable 
Day of week 
Mon Tues Wed Thurs Fri Sat Sun Mon Tues 
 December 2014 
Wastewater flow (m3 d-1) 32,444 36,843 34,363 42,651 38,857 40,247 38,266 36,369 - 
Rainfall (mm) 0.0 1.0 3.7 15.9 0.0 0.2 0.2 0.4 - 
 June 2015 
Wastewater flow (m3 d-1) - - 26,284 23,891 23,652 22,915 22,529 29,163 25,695 
Rainfall (mm) - - 1.1 0.0 0.0 0.0 0.0 0.0 0.0 
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Table S5. Toxicological information for fluoxetine towards aquatic test species 
Trophic 
level 
Test species EC50  
(mg L-1) 
LC50  
(mg L-1) 
LOEC  
(µg L-1) 
NOEC  
(µg L-1) 
Reference PNEC  
(µg L-1) 
Algae Dunaliella tertiolecta 0.170 - - - DeLorenzo 
and Fleming4 
0.170 
 Pseudokirchneriella 
subcapitata 
 
0.024 - - - Brooks et al5 0.024 
 Desmodesmus 
subspicatus 
- - ≤0.6 <0.6 Oakes et al6 0.060 
Fish Gambusia affinis - 0.546 - - Henry and 
Black7 
0.546 
 Pimephales promelas - 0.705 - - Brooks et al5 0.705 
Crustacean Ceriodaphnia dubia - 0.234 - - Brooks et al5 0.234 
 Ceriodaphnia dubia - 0.510 - - Henry et al8 0.510 
 Daphnia magna - 0.820 - - Brooks et al5 0.820 
 Gammarus pulex - - 0.100 - De Lange et 
al9 
0.010 
 Hyallea azteca - - 100 33 Péry et al10 3.30 
 Daphnia magna - - 31 8.9 Péry et al10 0.890 
 Daphnia magna - - 135 <60 Oakes et al6 6.00 
Mollusc Potamopyrgus 
antipodaram 
- - 69 13 Péry et al10 0.130 
 Potamopyrgus 
antipodaram 
- - - 0.47 Nentwig11 0.047 
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